If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
In Food and Allied Workers Union and Another v The Cold Chain, an important case in South African labour law, the Labour Court held that there was nothing absurd in permitting a senior managerial employee to participate in the activities of a trade union, provided that the employee complies with his contractual obligations. In this case, the employee was offered a managerial position as an alternative to retrenchment, on condition that he no longer participated in the activities of the trade union. When he refused, he was retrenched. The court did not hesitate to find the dismissal to be automatically unfair.
=== Rings === Ringworld-like megastructures exist in the Culture universe; the texts refer to them simply as "Rings" (with a capital R). As opposed to the smaller orbitals which revolve around a star, these structures are massive and completely encircle a star. Banks does not describe these habitats in detail, but records one as having been destroyed (along with three Spheres) in the Idiran-Culture war. In Matter, the Morthanveld people possesses ringworld-like structures made of innumerable various-sized tubes. Those structures, like Niven's Ringworld, encircle a star and are about the same size.
The triangular teeth can reach 7.5 cm (3.0 in). In juveniles, they are elongated and pointy but become broader and more serrated as they develop into adults. This reflects a shift from a diet mainly of fish to the incorporation of marine mammals. The front teeth are adapted for penetrating prey while the rear teeth, flattened at the sides and bent backwards, are designed for tearing. A total of around 300 teeth are arranged in rows like a conveyor belt, with teeth at the back moving to replace those at the front. The jaws are separate from the skull and are connected to the body entirely by muscles and tendons, allowing them to extend forward. A 2008 study using a computer scan of a 2.5 m (8.2 ft) long and 240 kg (530 lb) juvenile white shark determined that the specimen could exert a bite force of 1,602 newtons (360 lbf) in the front and 3,131 newtons (704 lbf) in the back. From this, the researchers calculated that a specimen 6.4 m (21 ft) long and weighing 3,324 kg (7,328 lb) could exert a bite force of 9,320 newtons (2,100 lbf) in the front and 18,216 newtons (4,095 lbf) in the back. The jaws are strengthened by mineralized cartilage; this is lacking in young white sharks, which have to eat softer food.
Sizeup: This is scouting and planning safe cuts for the felling direction, danger zones, and retreat paths, before starting the saw. The tree's location relative to other objects, support, and tension determines a safe fall, splits off, or if the saw will jam. Several factors to consider are tree lean and bend, wind direction, branch arrangement, snow load, obstacles and damaged, rotting tree parts, which might behave unexpectedly when cut. A tree may have to fall in its natural direction if it is too dangerous or impossible to fell in a desired direction. The aim is for the tree to fall safely for limbing and cross-cutting the log. The goal is to avoid having the tree fall on another tree or obstacle. Felling: After clearing the tree's base undergrowth for the retreat path and the felling direction; felling is properly done with three main cuts. To control the fall, the directional cut line should run 1/4 of the tree diameter to make a 45-degree wedge, which should be in the felling direction and horizontal. The top cut should be made first and then the bottom cut to form the directional line at the wedge point. A narrow or nonexistent hinge lessens felling direction control. From the opposite side of the wedge, the final felling cut is finished one-tenth of the tree diameter from the direction cut line. The felling cut is made horizontally and slightly 5 cm (2 in)) above the bottom cut. When the hinge is properly set, the felling cut will begin the fall in the desired direction. A sitback is when a tree moves back opposite the intended direction.
=== Agriculture === For plants to properly grow in dry areas they will need a usable xerotolerant microbiome. In desert plants xerophiles are set in a plant's microbiome helping with its water management.
Sources: en.wikipedia.org
=== Selected publications === 2023, The Information Theory of Aging, Nature Aging 2023, Chemically induced reprogramming to reverse cellular aging, Aging 2023, Loss of epigenetic information as a cause of mammalian aging, Cell 2021, The economic value of targeting aging, Nature Aging 2020, Reprogramming to recover youthful epigenetic information and restore vision, Nature 2008, SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging, Cell
transgene Any gene or other segment of genetic material that has been isolated from one organism and then transferred either naturally or by any of a variety of genetic engineering techniques into another organism, especially one of a different species. Transgenes are usually introduced into the second organism's germ line. They are commonly used to study gene function or to confer an advantage not otherwise available in the unaltered organism.
Nanocarbon: From Graphene to Buckyballs. Interactive 3D models of cyclohexane, benzene, graphene, graphite, chiral & non-chiral nanotubes, and C60 Buckyballs – WeCanFigureThisOut.org. C60 and Carbon Nanotubes a short video explaining how nanotubes can be made from modified graphite sheets and the three different types of nanotubes that are formed Learning module for Bandstructure of Carbon Nanotubes and Nanoribbons Selection of free-download articles on carbon nanotubes WOLFRAM Demonstrations Project: Electronic Band Structure of a Single-Walled Carbon Nanotube by the Zone-Folding Method WOLFRAM Demonstrations Project: Electronic Structure of a Single-Walled Carbon Nanotube in Tight-Binding Wannier Representation
==== Dame Commander of the Order of the British Empire (DBE) ==== Civil Dr Margaret Ebunoluwa Aderin, , Chancellor, University of Leicester. For services to Science Education and to Diversity. Amanda Jayne Blanc, Group Chief Executive Officer, Aviva. For services to Business, to Gender Equality and to Net-Zero. Professor Sonia Boyce, , Artist. For services to Art. Jilly Cooper, , Author. For services to Literature and to Charity. Felicity Ann Dahl, Founder, Roald Dahl's Marvellous Children's Charity and the Roald Dahl Museum and Story Centre. For services to Philanthropy, to Literature and to Young People. Dr Jennifer Dixon, , Chief Executive, The Health Foundation. For services to the NHS and to Public Health. Tristina Adele Harrison, Chief Executive Officer, TalkTalk Group. For services to Telecommunications. Dianne Michèle Jeffrey, , lately Trustee and Founder Chair, Age International. For services to Older People Abroad and to the community in Derbyshire. Professor Valerie Joan Lund, , Emeritus Professor in Rhinology, University College London. For services to Rhinology. Siobhain Ann McDonagh, , Member of Parliament for Mitcham and Morden. For Parliamentary and Political Service. Ruth Elizabeth Miskin, , Children's Reading Expert, Read Write Inc. For services to Education. Marit Mohn, Philanthropist. For services to Philanthropy. Professor Molly Morag Stevens, , John Black Professor of Bionanoscience, University of Oxford and Professor, Imperial College London. For services to Medicine.
==== Mass Spectrometry-based Proteomic Methods ==== Conventional shotgun proteomics identification of low abundance proteins in samples remains limited despite advances in Mass Spectrometry (MS) technology. While abundant proteins can be easily detected, possible protease substrates of biological significance, such as cytokines, can be easily overlooked due to their low abundance. Most pre-clearing strategies designed to correct this also risk losing low abundant proteins, thus techniques designed specifically to target protease substrates for identification have been developed. These techniques have coalesced into a new field of positional proteomics or terminomics aimed at identifying protein N- or C-terminal modifications of protease substrates. Terminomic approaches including Terminal Amine Isotopic Labeling of Substrates (TAILS) N-Terminomics, Combined FRActional Diagonal Chromatography (COFRADIC), and C-Terminomics add the level of stringency to conventional shotgun proteomics necessary to make them workhorse of degradomics. TAILS, or “N-Terminomics,” was designed and developed by the Overall Lab to overcome the functional limitations of conventional proteomics by enriching both mature N-terminal peptides and newly generated N-terminal peptides of proteins produced by protease activity. Formaldehyde or isobaric tags including Isotope-coded Affinity Tags (ICAT), 4 to 8 plex Isobaric tag for relative and absolute quantification (iTRAQ), or 10plex Tandem mass tags (TMT) block primary amines prior to trypsin digestion of proteome samples.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.